Skip to main content
TipRanks
Go Ultimate75% OFF
Sparrow Pharmaceuticals logo

Sparrow Pharmaceuticals: Valuation, Funding & Investors

75 State St Suite 100 Boston, Massachusetts 02109, UShttps://www.sparrowpharma.com/Therapeutics

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company focused on improving outcomes for patients with type 2 diabetes and related metabolic conditions. The company's lead candidate, clofutriben, is an oral HSD-1 inhibitor designed to address elevated cortisol levels, a key factor in treatment resistance and disease progression. Clofutriben aims to complement existing antidiabetic therapies by offering a novel mechanism of action that enhances glycemic control and addresses a spectrum of metabolic dysfunctions.

Leadership & Board

Current Number of Employees
19
Current LinkedIn Followers
3,333

Latest Estimated Valuation

Total Amount Raised
$95M
Total Funding Rounds
1
Latest Funding Amount
$95M
Latest Funding Round
Series B

Company Momentum

Positive
Articles Published on TipRanks1
LinkedIn Trend+0.91% followers
Workforce Trend+0.0% employees

Sparrow Pharmaceuticals LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.

Employee Trend

Sparrow Pharmaceuticals had 19 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.

19Latest Employee Count
0(0.00%)Week-Over-Week Change
05101520Apr 27, 2026May 11, 2026May 25, 2026Jun 08, 2026Jun 22, 2026Jul 06, 2026Jul 27, 2026Aug 10, 2026Aug 24, 2026Sep 07, 2026Sep 21, 2026Oct 05, 2026Oct 19, 2026Nov 02, 2026Nov 16, 2026

Social Trend

Sparrow Pharmaceuticals had 3,333 followers as of November 16, 2026. The number of followers increased by 30 (0.91%) week-over-week.

3,333Latest Followers Count
30(0.91%)Week-Over-Week Change
01,0002,0003,0004,000Apr 27, 2026May 11, 2026May 25, 2026Jun 08, 2026Jun 22, 2026Jul 06, 2026Jul 27, 2026Aug 10, 2026Aug 24, 2026Sep 07, 2026Sep 21, 2026Oct 05, 2026Oct 19, 2026Nov 02, 2026Nov 16, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Sep 24, 2025Series B$95.00M―

Investors

Investor NameFunding Round
OrbiMedSeries B
RA Capital ManagementSeries B
ForbionSeries B
U.S. Venture PartnersSeries B
RiverVestSeries B

Similar Companies

A snapshot of private companies similar to Sparrow Pharmaceuticals, helping you discover and navigate related company profiles.

Related News and Analysis